Idazoxan Inhibits Hyperprolactinaemia in Ovariectomized Estrogen-Treated Rats

Summary The α2-antagonist idazoxan (IDZ) has previously been shown to inhibit hyperprolactinaemia triggered by various stimuli such as lactation, stress, serotonergic agents and morphine (PREZIOSI, MARTIRE, NAVARRA, PISTRITTO and VACCA 1989; KRULICH, JURCOVICOVA and LE 1989). In this study, we inves...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hormone and metabolic research 1991-01, Vol.23 (1), p.22-24
Hauptverfasser: Navarra, P., Eechaute, W., Preziosi, P., Lacroix, E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary The α2-antagonist idazoxan (IDZ) has previously been shown to inhibit hyperprolactinaemia triggered by various stimuli such as lactation, stress, serotonergic agents and morphine (PREZIOSI, MARTIRE, NAVARRA, PISTRITTO and VACCA 1989; KRULICH, JURCOVICOVA and LE 1989). In this study, we investigated the PRL-lowering activity of IDZ in ovariectomized estrogen-treated (OET) rats; since a PRL surge usually occurs in normal cycling rats on the day of proestrus, the effect of IDZ on pulsatile PRL release in intact female rats was also studied. IDZ significantly lowered plasma PRL levels in OET rats; no elevated PRL values were observed in normal cycling rats, indicating that IDZ might inhibit PRL surges in these animals. It is concluded that IDZ is an effective PRL-lowering agent in a number of physiological and pharmacological hyperprolactinaemic models.
ISSN:0018-5043
1439-4286
DOI:10.1055/s-2007-1003602